Até recentemente, a regulação da Cannabis medicinal (CM) no Brasil, baseava-se em normas que eram insuficientes para abordar integralmente os aspectos sanitários da CM. Em fevereiro de 2026, a Anvisa publicou um conjunto de normas, as Resoluções da Diretoria Colegiada (RDCs) 1011, 1012, 1013, 1014 e 1015, que abordam a CM, desde a atualização da Lista de Substância Sujeitas a Controle Especial, passando pelo cultivo, pesquisa, produção, controle de qualidade e experimentação regulatória (Ambiente Regulatório Especial - Sandbox Regulatório). Estima-se que essas normas tenham trazido uma mudança bastante significativa para a regulação, com consequências potenciais sobre pesquisa e geração de evidências, para sua utilização no âmbito do SUS e para a judicialização do acesso. No entanto, persistem desafios, como a clareza da regulação no que tange ao controle especial, a necessidade de integrar instâncias governamentais, inclusive a Anvisa, na implementação das normas, dificuldades dos produtores de CM para ajustar-se a elas e, principalmente, em relação à persistente lacuna da regulação das importações. Os desdobramentos positivos dependerão do fortalecimento da agenda de pesquisa e da produção de evidências para subsidiar incorporação tecnológica e financiamento público.
Palavras-chave:
Cannabis medicinal, regulação sanitária, políticas públicas de saúde
Abstract:
Until recently, the regulation of medical Cannabis (MC) in Brazil was based on norms that did not comprehensively address its sanitary and regulatory dimensions. In February 2026, the Brazilian Health Regulatory Agency (Anvisa) issued a new set of regulations—Collegiate Board Resolutions (RDCs) 1,011, 1,012, 1,013, 1,014, and 1,015—covering MC from the updating of the List of Controlled Substances to cultivation, research, production, quality control, and regulatory experimentation (Regulatory Sandbox). These regulations are expected to represent a significant shift in the regulatory framework, with potential implications for research and evidence generation, its use within the Brazilian Unified Health System (SUS), and litigation for access. However, important challenges remain, including regulatory clarity regarding controlled substances, the need for coordination among governmental bodies—including Anvisa—in implementing the new framework, difficulties faced by producers in adapting to the new requirements, and, notably, the persistent regulatory gap concerning imports. Positive outcomes will depend on strengthening the research agenda and on the production of robust evidence to support health technology incorporation and public financing.
Keywords:
medical Cannabis, health regulation, public health policy
Challenges for the new regulation on medical Cannabis in Brazil
Resumo (abstract):
Until recently, the regulation of medical Cannabis (MC) in Brazil was based on norms that did not comprehensively address its sanitary and regulatory dimensions. In February 2026, the Brazilian Health Regulatory Agency (Anvisa) issued a new set of regulations—Collegiate Board Resolutions (RDCs) 1,011, 1,012, 1,013, 1,014, and 1,015—covering MC from the updating of the List of Controlled Substances to cultivation, research, production, quality control, and regulatory experimentation (Regulatory Sandbox). These regulations are expected to represent a significant shift in the regulatory framework, with potential implications for research and evidence generation, its use within the Brazilian Unified Health System (SUS), and litigation for access. However, important challenges remain, including regulatory clarity regarding controlled substances, the need for coordination among governmental bodies—including Anvisa—in implementing the new framework, difficulties faced by producers in adapting to the new requirements, and, notably, the persistent regulatory gap concerning imports. Positive outcomes will depend on strengthening the research agenda and on the production of robust evidence to support health technology incorporation and public financing.
Palavras-chave (keywords):
medical Cannabis, health regulation, public health policy
Osorio-de-Castro, CGS, Esher, A, Oliveira, CVS, Santos-Pinto, CDB. Desafios para o novo marco regulatório da Cannabis medicinal no Brasil. Cien Saude Colet [periódico na internet] (2026/mar). [Citado em 14/08/2026].
Está disponível em: http://cienciaesaudecoletiva.com.br/artigos/desafios-para-o-novo-marco-regulatorio-da-cannabis-medicinal-no-brasil/19962?id=19962&id=19962
